NVO News

Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage Ready to Announce with Confidence?

Semaglutide Preparations Market - Global Forecast 2025-2030 Featuring Novo Nordisk, Gan & Lee Pharmaceuticals, Shanghai Fosun Pharmaceutical, and Luye Pharmaceutical

FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Sunlight.com Survey: 1 in 7 Americans Plan To Use GLP-1s in 2026

Clinic Secret Unveiled: How This GLP-1 Weight Loss Platform Enables At-Home Access to Ozempic, Semaglutide & Tirzepatide - Clinic Secret

Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management USA - English USA - English

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management USA - English USA - English